# The TAK-003 story: key decisions that shaped development of a tetravalent dengue vaccine

## TL;DR

This paper reviews the key decisions made during the development of TAK-003, a tetravalent dengue vaccine, highlighting its design and testing process.

## Contribution

The paper outlines the rationale behind critical development choices for TAK-003, a dengue vaccine, offering insights into its design and evaluation.

## Key findings

- TAK-003's development involved decisions on vaccine composition and safety assessments.
- The vaccine's dosing schedule and immunogenicity were carefully evaluated.
- A pivotal phase 3 study was designed to assess the vaccine's efficacy.

## Abstract

The approved, live-attenuated tetravalent dengue vaccine TAK-003 has undergone extensive preclinical and clinical assessment. This review provides an overview of the rationale for some key decisions made during TAK-003 development. These include decisions around vaccine composition, assessment of factors that may be associated with the safety of live-attenuated viral vaccines, dosing schedule, immunogenicity assessments, and design of the pivotal phase 3 efficacy study.